Dysregulated B cell expression of RANKL and OPG correlates with loss of bone mineral density in HIV infection

Kehmia Titanji, Aswani Vunnava, Anandi N Sheth, Cecile Delille, Jeffrey L Lennox, Sara E Sanford, Antonina Foster, Andrea Knezevic, Kirk A Easley, M Neale Weitzmann, Ighovwerha Ofotokun, Kehmia Titanji, Aswani Vunnava, Anandi N Sheth, Cecile Delille, Jeffrey L Lennox, Sara E Sanford, Antonina Foster, Andrea Knezevic, Kirk A Easley, M Neale Weitzmann, Ighovwerha Ofotokun

Abstract

HIV infection is associated with high rates of osteopenia and osteoporosis, but the mechanisms involved are unclear. We recently reported that bone loss in the HIV transgenic rat model was associated with upregulation of B cell expression of the key osteoclastogenic cytokine receptor-activator of NF-κB ligand (RANKL), compounded by a simultaneous decline in expression of its physiological moderator, osteoprotegerin (OPG). To clinically translate these findings we performed cross-sectional immuno-skeletal profiling of HIV-uninfected and antiretroviral therapy-naïve HIV-infected individuals. Bone resorption and osteopenia were significantly higher in HIV-infected individuals. B cell expression of RANKL was significantly increased, while B cell expression of OPG was significantly diminished, conditions favoring osteoclastic bone resorption. The B cell RANKL/OPG ratio correlated significantly with total hip and femoral neck bone mineral density (BMD), T- and/or Z-scores in HIV infected subjects, but revealed no association at the lumbar spine. B cell subset analyses revealed significant HIV-related increases in RANKL-expressing naïve, resting memory and exhausted tissue-like memory B cells. By contrast, the net B cell OPG decrease in HIV-infected individuals resulted from a significant decline in resting memory B cells, a population containing a high frequency of OPG-expressing cells, concurrent with a significant increase in exhausted tissue-like memory B cells, a population with a lower frequency of OPG-expressing cells. These data validate our pre-clinical findings of an immuno-centric mechanism for accelerated HIV-induced bone loss, aligned with B cell dysfunction.

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Figure 1. Increased frequency of RANKL-expressing B…
Figure 1. Increased frequency of RANKL-expressing B cells and decreased frequency of OPG-expressing B cells in HIV infection.
Intracellular expression of: A) OPG and B) RANKL, by circulating peripheral blood B cells were quantified by flow cytometry in 56 HIV-negative and 57 HIV-infected individuals. Comparisons between HIV sero status were performed using Wilcoxon rank-sum test.
Figure 2. B cell subset RANKL and…
Figure 2. B cell subset RANKL and OPG expression in HIV-negative and HIV-positive individuals.
A) Total B cells (CD3−CD20+ cells) were identified in the lymphocyte gate. B) B cells were further divided into 4 distinct subsets: naïve (CD21hiCD27−), resting memory (CD21hiCD27+), activated memory (CD21−CD27+), and exhausted tissue-like memory (CD21−CD27−). C) B cell subset distribution in HIV-negative (N = 28) and seropositive (N = 24) individuals. Intracellular expression of D) OPG and E) RANKL in B cell subsets of HIV-negative and seropositive individuals combined. Graphs reflect individual individuals with bars at the mean (parametric data) or median [non-parametric data, Activated and tissue-like memory subset (C) and naïve and resting memory (E)]. Simple comparisons were done using Student's t test (for parametric data) or Wilcoxon rank sum test (for non-parametric data) for each of the subsets (C) and one-way ANOVA was used to compare multiple groups (D). Actual P values are reported for simple comparisons. For ANOVA *P<0.05 or ***P<0.001 or P =  not significant (ns).
Figure 3. Differential B cell subset RANKL…
Figure 3. Differential B cell subset RANKL and OPG expression in HIV-negative and HIV-positive individuals.
Representative histograms (alternate top panels) of B cell subset staining for RANKL (A) and OPG (B) for HIV negative individuals (solid line) and HIV positive individuals (dashed line). Scatter plots (alternate bottom panels) represent cumulative data for B cell subset RANKL (A) or OPG (B) expression from individual HIV-negative (HIV−, N = 17) or seropositive (HIV+, N = 15) individuals with bars at the mean (parametric data) or median [non-parametric data, RANKL: tissue-like memory (HIV-); OPG: All HIV- subsets]. Comparisons were done using two-way ANOVA, followed by pairwise comparisons of individual B cell subsets using student's t-test (parametric data) or Wilcoxon rank sum test (non-parametric data).
Figure 4. Immunocentric model of HIV induced…
Figure 4. Immunocentric model of HIV induced bone loss.
We propose a model for HIV- induced bone loss whereby HIV infection, either through direct effects on B cells, or though disruption of T cell costimulation of the humoral system, leads to a decline in the frequency of B cells secreting OPG, coupled with an increase in the frequency of B cells secreting RANKL. This disruption of the immuno-skeletal interface results in an increase in the RANKL/OPG ratio that is permissive for osteoclast formation and enhanced bone resorption, which ultimately contributes to bone loss and the elevated bone fracture risk characteristic of HIV-infected individuals.

References

    1. Gandhi RT, Sax PE, Grinspoon SK (2012) Metabolic and cardiovascular complications in HIV-infected patients: new challenges for a new age. J Infect Dis 205 Suppl 3 S353–354.
    1. Guaraldi G, Orlando G, Zona S, Menozzi M, Carli F, et al. (2011) Premature age-related comorbidities among HIV-infected persons compared with the general population. Clin Infect Dis 53: 1120–1126.
    1. Tebas P, Powderly WG, Claxton S, Marin D, Tantisiriwat W, et al. (2000) Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS 14: F63–67.
    1. Brown TT, Qaqish RB (2006) Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS 20: 2165–2174.
    1. McComsey GA, Tebas P, Shane E, Yin MT, Overton ET, et al. (2010) Bone disease in HIV infection: a practical review and recommendations for HIV care providers. Clinical infectious diseases 51: 937–946.
    1. Bruera D, Luna N, David DO, Bergoglio LM, Zamudio J (2003) Decreased bone mineral density in HIV-infected patients is independent of antiretroviral therapy. AIDS 17: 1917–1923.
    1. Grijsen ML, Vrouenraets SM, Steingrover R, Lips P, Reiss P, et al. (2010) High prevalence of reduced bone mineral density in primary HIV-1-infected men. Aids 24: 2233–2238.
    1. Mondy K, Yarasheski K, Powderly WG, Whyte M, Claxton S, et al. (2003) Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. Clin Infect Dis 36: 482–490.
    1. Schafer JJ, Manlangit K, Squires KE (2013) Bone health and human immunodeficiency virus infection. Pharmacotherapy 33: 665–682.
    1. Bolland MJ, Grey A (2011) HIV and Low Bone Density: Responsible Party, or Guilty by Association? IBMS BoneKEy 8: 7–15.
    1. Guaraldi G, Ventura P, Albuzza M, Orlando G, Bedini A, et al. (2001) Pathological fractures in AIDS patients with osteopenia and osteoporosis induced by antiretroviral therapy. AIDS 15: 137–138.
    1. Triant VA, Brown TT, Lee H, Grinspoon SK (2008) Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system. J Clin Endocrinol Metab 93: 3499–3504.
    1. Young B, Dao CN, Buchacz K, Baker R, Brooks JT (2011) Increased Rates of Bone Fracture among HIV-Infected Persons in the HIV Outpatient Study (HOPS) Compared with the US General Population, 2000–2006. Clin Infect Dis. 2011/03/15 ed.
    1. Womack JA, Goulet JL, Gibert C, Brandt C, Chang CC, et al. (2011) Increased risk of fragility fractures among HIV infected compared to uninfected male veterans. PLoS One 6: e17217.
    1. Prior J, Burdge D, Maan E, Milner R, Hankins C, et al. (2007) Fragility fractures and bone mineral density in HIV positive women: a case-control population-based study. Osteoporos Int 18: 1345–1353.
    1. Guerri-Fernandez R, Vestergaard P, Carbonell C, Knobel H, Aviles FF, et al. (2013) HIV infection is strongly associated with hip fracture risk, independently of age, gender, and comorbidities: a population-based cohort study. J Bone Miner Res 28: 1259–1263.
    1. Teitelbaum SL (2000) Bone resorption by osteoclasts. Science 289: 1504–1508.
    1. Khosla S (2001) Minireview: the OPG/RANKL/RANK system. Endocrinology 142: 5050–5055.
    1. Yun TJ, Chaudhary PM, Shu GL, Frazer JK, Ewings MK, et al. (1998) OPG/FDCR-1, a TNF receptor family member, is expressed in lymphoid cells and is up-regulated by ligating CD40. J Immunol 161: 6113–6121.
    1. Toraldo G, Roggia C, Qian WP, Pacifici R, Weitzmann MN (2003) IL-7 induces bone loss in vivo by induction of receptor activator of nuclear factor kappa B ligand and tumor necrosis factor alpha from T cells. Proc Natl Acad Sci U S A 100: 125–130.
    1. Weitzmann MN (2013) The Role of Inflammatory Cytokines, the RANKL/OPG Axis, and the Immunoskeletal Interface in Physiological Bone Turnover and Osteoporosis. Scientifica 2013: 1–29.
    1. Weitzmann MN, Pacifici R (2006) Estrogen deficiency and bone loss: an inflammatory tale. J Clin Invest 116: 1186–1194.
    1. Moir S, Ho J, Malaspina A, Wang W, DiPoto AC, et al. (2008) Evidence for HIV-associated B cell exhaustion in a dysfunctional memory B cell compartment in HIV-infected viremic individuals. J Exp Med 205: 1797–1805.
    1. Day CL, Kaufmann DE, Kiepiela P, Brown JA, Moodley ES, et al. (2006) PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 443: 350–354.
    1. Vikulina T, Fan X, Yamaguchi M, Roser-Page S, Zayzafoon M, et al. (2010) Alterations in the immuno-skeletal interface drive bone destruction in HIV-1 transgenic rats. Proc Natl Acad Sci U S A 107: 13848–13853.
    1. Li Y, Toraldo G, Li A, Yang X, Zhang H, et al. (2007) B cells and T cells are critical for the preservation of bone homeostasis and attainment of peak bone mass in vivo. Blood 109: 3839–3848.
    1. Onal M, Xiong J, Chen X, Thostenson JD, Almeida M, et al. (2012) Receptor activator of nuclear factor kappaB ligand (RANKL) protein expression by B lymphocytes contributes to ovariectomy-induced bone loss. J Biol Chem 287: 29851–29860.
    1. Kawai T, Matsuyama T, Hosokawa Y, Makihira S, Seki M, et al. (2006) B and T lymphocytes are the primary sources of RANKL in the bone resorptive lesion of periodontal disease. Am J Pathol 169: 987–998.
    1. Moir S, Fauci AS (2009) B cells in HIV infection and disease. Nat Rev Immunol 9: 235–245.
    1. Titanji K, De Milito A, Cagigi A, Thorstensson R, Grutzmeier S, et al. (2006) Loss of memory B cells impairs maintenance of long-term serologic memory during HIV-1 infection. Blood 108: 1580–1587.
    1. Manolagas SC, Jilka RL (1995) Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. N Engl J Med 332: 305–311.
    1. Shimizu Y, Sakai A, Menuki K, Mori T, Isse T, et al. (2011) Reduced bone formation in alcohol-induced osteopenia is associated with elevated p21 expression in bone marrow cells in aldehyde dehydrogenase 2-disrupted mice. Bone 48: 1075–1086.
    1. Collin F, Duval X, Le Moing V, Piroth L, Al Kaied F, et al. (2009) Ten-year incidence and risk factors of bone fractures in a cohort of treated HIV1-infected adults. AIDS 23: 1021–1024.
    1. Cotter AG, Sabin CA, Simelane S, Macken A, Kavanagh E, et al. (2014) Relative contribution of HIV infection, demographics and body mass index to bone mineral density. AIDS 28: 2051–2060.
    1. Hui SL, Slemenda CW, Johnston CC Jr (1988) Age and bone mass as predictors of fracture in a prospective study. J Clin Invest 81: 1804–1809.
    1. Arora S, Agrawal M, Sun L, Duffoo F, Zaidi M, et al. (2010) HIV and bone loss. Current osteoporosis reports 8: 219–226.
    1. Gibellini D, Borderi M, De Crignis E, Cicola R, Vescini F, et al. (2007) RANKL/OPG/TRAIL plasma levels and bone mass loss evaluation in antiretroviral naive HIV-1-positive men. J Med Virol 79: 1446–1454.
    1. Dolan SE, Huang JS, Killilea KM, Sullivan MP, Aliabadi N, et al. (2004) Reduced bone density in HIV-infected women. Aids 18: 475–483.
    1. Ueland T, Bollerslev J, Godang K, Muller F, Froland SS, et al. (2001) Increased serum osteoprotegerin in disorders characterized by persistent immune activation or glucocorticoid excess–possible role in bone homeostasis. Eur J Endocrinol 145: 685–690.
    1. Hwang JJ, Wei J, Abbara S, Grinspoon SK, Lo J (2012) Receptor activator of nuclear factor-kappaB ligand (RANKL) and its relationship to coronary atherosclerosis in HIV patients. J Acquir Immune Defic Syndr 61: 359–363.
    1. Brown TT, Chen Y, Currier JS, Ribaudo HJ, Rothenberg J, et al. (2013) Body composition, soluble markers of inflammation, and bone mineral density in antiretroviral therapy-naive HIV-1-infected individuals. J Acquir Immune Defic Syndr 63: 323–330.
    1. Kanis JA (2002) Diagnosis of osteoporosis and assessment of fracture risk. Lancet 359: 1929–1936.
    1. Eghbali-Fatourechi G, Khosla S, Sanyal A, Boyle WJ, Lacey DL, et al. (2003) Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest 111: 1221–1230.

Source: PubMed

3
订阅